

Consensus or Controversy? Clinical Investigators Provide Perspectives on the Current and Future Management of Ovarian Cancer**THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.**

- 1. Which of the following statements best reflects progression-free survival (PFS) outcomes from the 3.5-year follow-up of the Phase III PRIMA trial of maintenance niraparib for patients with newly diagnosed advanced ovarian cancer (OC)?**
 - a. PFS benefit was lost in patients with BRCA or other homologous recombination deficiency (HRD) gene mutations
 - b. PFS benefit was maintained in the BRCA mutation group only
 - c. PFS benefit was maintained in patients with BRCA and other HRD gene mutations**
- 2. Which of the following outcomes was observed with olaparib maintenance after 7 years of follow-up in the Phase III SOLO-1 study?**
 - a. No benefit in overall survival (OS)
 - b. A nonsignificant trend in OS benefit
 - c. A statistically significant benefit in OS**
- 3. Which of the following populations of patients with advanced OC derived a statistically significant PFS benefit from the combination of first-line chemotherapy/bevacizumab/durvalumab followed by maintenance bevacizumab/durvalumab/olaparib in the Phase III DUO-O trial?**
 - a. Patients with HRD-positive disease
 - b. Patients with HRD-negative disease
 - c. Both a and b**
 - d. Neither a nor b
- 4. What was the approximate confirmed objective response rate among patients receiving trastuzumab deruxtecan for HER2 IHC 3+ advanced OC in the Phase II DESTINY-PanTumor02 trial?**
 - a. 20%
 - b. 40%
 - c. More than 60%**
- 5. Which of the following descriptions best reflects the mechanism of action of nemvaleukin alfa?**
 - a. Folate receptor alpha-directed antibody-drug conjugate
 - b. IL-2 variant**
 - c. Glucocorticoid receptor modulator
 - d. Anti-PD-1 monoclonal antibody